Older men with type 2 diabetes who received metformin or newer hypoglycemic medication had less cognitive decline compared with those who received sulfonylureas.
All articles by Rachael Beairsto
Dr Gottlieb expressed that the FDA is committed to bringing competition to the insulin market to lower prices and expand patient access.
Publish Date
-
Latest News Your top articles for Wednesday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses
